Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Intellia Therapeutics is a clinical-stage CRISPR gene-editing company developing in vivo (direct injection) and ex vivo (cell-based) therapies for genetic diseases. The company's lead program NTLA-2001 for transthyretin amyloidosis (ATTR) represents the first systemically delivered CRISPR therapeutic in human trials, with potential regulatory filings anticipated in 2026-2027. Intellia's competitive advantage lies in its lipid nanoparticle delivery platform enabling direct in vivo editing, differentiating it from ex vivo CAR-T approaches.
Intellia operates a dual-track model: (1) partnered programs where it receives upfront payments, development milestones, and royalties on future sales (e.g., Regeneron collaboration on hemophilia A/B), and (2) wholly-owned programs where it retains 100% economics but bears full development costs. The company's pricing power will depend on demonstrating durable gene editing with single-dose administration versus chronic therapies. Current burn rate of approximately $300M annually is funded by $650M+ cash position (6+ quarters of runway based on Q4 2025 estimates). Revenue is episodic and milestone-driven until commercial launch.
NTLA-2001 Phase 3 ATTR amyloidosis trial data readouts and regulatory filing timelines (primary catalyst)
Clinical data from hemophilia A/B programs (partnered with Regeneron) demonstrating durability of editing
Expansion of in vivo editing platform to new indications (oncology, autoimmune) and IND filings
Partnership announcements with upfront payments and validation of technology platform
Competitive developments from CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, and Verve Therapeutics
FDA guidance on gene-editing regulatory pathways and manufacturing standards
Regulatory uncertainty around gene-editing therapies with limited precedent (only two approved CRISPR therapies as of 2026, both ex vivo)
Manufacturing complexity and scalability of lipid nanoparticle delivery systems for commercial production
Long-term safety monitoring requirements may extend development timelines and increase costs beyond traditional small molecules
Reimbursement uncertainty for high-cost gene therapies (likely $500K-$2M+ per patient) amid payer scrutiny
CRISPR Therapeutics and Vertex partnership advancing competing ex vivo programs with earlier commercial traction
Base editing and prime editing technologies (Beam Therapeutics, Prime Medicine) may offer superior precision and safety profiles
Large pharma in-house gene-editing capabilities reducing partnership opportunities and milestone revenue
Patent litigation risk in crowded CRISPR IP landscape (Broad Institute vs. UC Berkeley foundational patents)
Cash burn of $300M+ annually requires equity raises within 18-24 months absent partnership influx
Dilution risk from future financings at potentially unfavorable valuations if clinical setbacks occur
Current 6.21x current ratio is strong but declining as R&D expenses accelerate into Phase 3 trials
low - Clinical development timelines are independent of GDP cycles. However, capital markets conditions affect ability to raise financing for cash-intensive R&D. Biotech sector correlates with risk appetite rather than economic fundamentals. Healthcare spending on rare disease treatments is relatively recession-resistant.
Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (products likely 2027+ launch). Pre-revenue biotechs are duration assets with negative near-term cash flows, making them highly sensitive to risk-free rate changes. Higher rates also increase cost of capital for future equity raises needed to fund development. Fed funds rate and 10-year Treasury yields directly affect biotech sector multiples.
Minimal direct credit exposure with 0.13x debt/equity ratio and $650M+ cash position. Company relies on equity markets rather than debt financing. However, tightening credit conditions reduce institutional investor appetite for speculative biotech, affecting stock liquidity and valuation multiples.
growth - Attracts speculative biotech investors focused on binary clinical catalysts and platform technology potential. Recent 47% three-month return reflects momentum trading around clinical milestones. Not suitable for value or income investors given negative earnings and no dividend. Institutional ownership includes specialized healthcare funds and venture-style public market investors willing to accept 3-5 year development timelines.
high - Clinical-stage biotech with binary event risk around trial data. Stock exhibits 60%+ annualized volatility typical of pre-revenue biotechs. Single clinical readout can move stock 30-50% in either direction. Low float and institutional concentration amplify price swings. Beta likely 1.5-2.0x relative to broader market.
